Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Debt (2020 - 2025)

Historic Non-Current Debt for Aytu Biopharma (AYTU) over the last 6 years, with Q4 2025 value amounting to $10.0 million.

  • Aytu Biopharma's Non-Current Debt rose 15.03% to $10.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.0 million, marking a year-over-year increase of 15.03%. This contributed to the annual value of $10.9 million for FY2025, which is 16.55% up from last year.
  • Aytu Biopharma's Non-Current Debt amounted to $10.0 million in Q4 2025, which was up 15.03% from $10.4 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Non-Current Debt registered a high of $15.0 million during Q4 2023, and its lowest value of $129000.0 during Q4 2021.
  • Moreover, its 5-year median value for Non-Current Debt was $10.9 million (2024), whereas its average is $10.3 million.
  • In the last 5 years, Aytu Biopharma's Non-Current Debt crashed by 9870.29% in 2021 and then skyrocketed by 1116589.15% in 2022.
  • Quarter analysis of 5 years shows Aytu Biopharma's Non-Current Debt stood at $129000.0 in 2021, then skyrocketed by 11165.89% to $14.5 million in 2022, then rose by 3.06% to $15.0 million in 2023, then tumbled by 33.35% to $10.0 million in 2024, then increased by 0.15% to $10.0 million in 2025.
  • Its Non-Current Debt stands at $10.0 million for Q4 2025, versus $10.4 million for Q3 2025 and $10.9 million for Q2 2025.